Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Seattle Genetics Reports Third Quarter 2019 Financial Results
October 29, 2019 4:02 PM EDT-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018-
-Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer Granted Priority Review by FDA; PDUFA Target Action Date March 15, 2020-
-Tucatinib HER2CLIMB Pivotal Trial Met Primary and Both Key Secondary Endpoints; New Drug Application to FDA Planned for the First Quarter of 2020-
-Conference Call Today at 4:30 p.m.... More
